FOS and neoplasm: To further validate the therapeutic potential of SF3A3 inhibition, we employed a patient‐derived tumor‐like cell cluster (PTC) model, which recapitulates patient tumor heterogeneity and drug response.[44, 45] PEITC exhibited strong anti‐tumor activity in PTCs, particularly when combined with the c‐FOS inhibitor T‐5224, demonstrating synergistic effects in reducing tumor cell viability.